Cargando…

Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2

Mutations in the gene coding for leucine-rich repeat kinase 2 (LRRK2) are a leading cause of the inherited form of Parkinson’s disease (PD), while LRRK2 overactivation is also associated with the more common idiopathic form of PD. LRRK2 is a large multidomain protein, including a GTPase as well as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Ranjan K., Soliman, Ahmed, Guaitoli, Giambattista, Störmer, Eliza, von Zweydorf, Felix, Dal Maso, Thomas, Oun, Asmaa, Van Rillaer, Laura, Schmidt, Sven H., Chatterjee, Deep, David, Joshua A., Pardon, Els, Schwartz, Thomas U., Knapp, Stefan, Kennedy, Eileen J., Steyaert, Jan, Herberg, Friedrich W., Kortholt, Arjan, Gloeckner, Christian Johannes, Versées, Wim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892280/ https://www.ncbi.nlm.nih.gov/pubmed/35217606 http://dx.doi.org/10.1073/pnas.2112712119

Ejemplares similares

Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies
por: Leemans, Margaux, et al.
Publicado: (2020)

Allosteric inhibition of LRRK2, where are we now
por: Soliman, Ahmed, et al.
Publicado: (2020)

A homologue of the Parkinson’s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover
por: Deyaert, Egon, et al.
Publicado: (2017)

Structural basis for the allosteric modulation of rhodopsin by nanobody binding to its extracellular domain
por: Wu, Arum, et al.
Publicado: (2023)

Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
por: Pathak, Pragya, et al.
Publicado: (2023)

Characterization of Lipopolysaccharide Effects on LRRK2 Signaling in RAW Macrophages
por: Oun, Asmaa, et al.
Publicado: (2023)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

A Conserved Role for LRRK2 and Roco Proteins in the Regulation of Mitochondrial Activity
por: Rosenbusch, Katharina E., et al.
Publicado: (2021)

Allosteric Nanobodies Reveal the Dynamic Range and Diverse Mechanisms of GPCR Activation
por: Staus, Dean P, et al.
Publicado: (2016)

LRRK2 Structure-Based Activation Mechanism and Pathogenesis
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains
por: Weng, Jui-Hung, et al.
Publicado: (2022)

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
por: Wojewska, Dominika Natalia, et al.
Publicado: (2021)

Capturing the domain crosstalk in full length LRRK2 and LRRK2(RCKW)
por: Störmer, Eliza, et al.
Publicado: (2023)

Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation
por: Gilsbach, Bernd K., et al.
Publicado: (2014)

Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease
por: Rosenbusch, Katharina E., et al.
Publicado: (2016)

Roco Proteins: GTPases with a Baroque Structure and Mechanism
por: Wauters, Lina, et al.
Publicado: (2019)

Editorial: LRRK2—Fifteen Years From Cloning to the Clinic
por: Rideout, Hardy, et al.
Publicado: (2022)

An improved yeast surface display platform for the screening of nanobody immune libraries
por: Uchański, Tomasz, et al.
Publicado: (2019)

Crystal structure of a heterodimer of editosome interaction proteins in complex with two copies of a cross-reacting nanobody
por: Park, Young-Jun, et al.
Publicado: (2012)

Nanobody Mediated Crystallization of an Archeal Mechanosensitive Channel
por: Löw, Christian, et al.
Publicado: (2013)

Structural basis of inhibition of lipid-linked oligosaccharide flippase PglK by a conformational nanobody
por: Perez, Camilo, et al.
Publicado: (2017)

Auto-regulation of Rab5 GEF activity in Rabex5 by allosteric structural changes, catalytic core dynamics and ubiquitin binding
por: Lauer, Janelle, et al.
Publicado: (2019)

The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant
por: Marku, Algerta, et al.
Publicado: (2020)

Domain-interface dynamics of CFTR revealed by stabilizing nanobodies
por: Sigoillot, Maud, et al.
Publicado: (2019)

In vivo and in vitro characterizations of melibiose permease (MelB) conformation-dependent nanobodies reveal sugar-binding mechanisms
por: Katsube, Satoshi, et al.
Publicado: (2023)

Mapping inhibitory sites on the RNA polymerase of the 1918 pandemic influenza virus using nanobodies
por: Keown, Jeremy R., et al.
Publicado: (2022)

Nanobody-enabled monitoring of kappa opioid receptor states
por: Che, Tao, et al.
Publicado: (2020)

SAXS analysis of the tRNA-modifying enzyme complex MnmE/MnmG reveals a novel interaction mode and GTP-induced oligomerization
por: Fislage, Marcus, et al.
Publicado: (2014)

Production, crystallization and X-ray diffraction analysis of two nanobodies against the Duffy binding-like (DBL) domain DBL6∊-FCR3 of the Plasmodium falciparum VAR2CSA protein. Corrigendum
por: Vuchelen, Anneleen, et al.
Publicado: (2013)

Guilt-by-Association – Functional Insights Gained From Studying the LRRK2 Interactome
por: Gloeckner, Christian Johannes, et al.
Publicado: (2020)

Targeting G protein-coupled receptor signaling at the G protein level with a selective nanobody inhibitor
por: Gulati, Sahil, et al.
Publicado: (2018)

Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021)

The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions
por: Carrion, Maria Dolores Perez, et al.
Publicado: (2017)

Conformational heterogeneity of the Roc domains in C. tepidum Roc–COR and implications for human LRRK2 Parkinson mutations
por: Rudi, Katharina, et al.
Publicado: (2015)

A structure of substrate-bound Synaptojanin1 provides new insights in its mechanism and the effect of disease mutations
por: Paesmans, Jone, et al.
Publicado: (2020)

Protein kinase C showcases allosteric control: activation of LRRK1
por: Tovell, Hannah, et al.
Publicado: (2023)

Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery
por: Taylor, Susan S., et al.
Publicado: (2020)

Structure of Nanobody Nb23
por: Percipalle, Mathias, et al.
Publicado: (2021)

Bypassing the Need for Cell Permeabilization: Nanobody CDR3 Peptide Improves Binding on Living Bacteria
por: Breine, A., et al.
Publicado: (2023)

Nanobody Mediated Inhibition of Attachment of F18 Fimbriae Expressing Escherichia coli
por: Moonens, Kristof, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8b16d1plmiu6vfj5d6ln9hualm